Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy.

导出 OA

翻译打印收藏纠错

作者： Kewen,He ^[1] ; Nahum,Puebla-Osorio ^[2] ; Hampartsoum B,Barsoumian ^[2] ; Duygu,Sezen ^[3] ; Zahid,Rafiq ^[2] ; Thomas S,Riad ^[2] ; Yun,Hu ^[2] ; Ailing,Huang ^[2] ; Tiffany A,Voss ^[2] ; Claudia S Kettlun,Leyton ^[2] ; Lily Jae,Schuda ^[2] ; Ethan,Hsu ^[2] ; Joshua,Heiber ^[4] ; Maria-Angelica,Cortez ^[2] ; James W,Welsh ^[5]

作者单位： Department of Radiation Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Jinan, Shandong, China. hekewen9144@foxmail.com.;Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. hekewen9144@foxmail.com. ^[1] Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. ^[2] Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.;Department of Radiation Oncology, Koç University School of Medicine, Istanbul, Turkey. ^[3] Mural Oncology PLC, Waltham, MA, United States. ^[4] Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. jwelsh@mdanderson.org. ^[5]

关键词 Abscopal And PD-1 Cancer IL-2 RDB 1462 Radiation